Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 05 Apr 2023
A new study led by a UCLA Health researcher found that pregnant women had a slightly increased risk of having children with autism spectrum disorder if the household tap water had higher lithium levels.
Read Full NewsA retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in patients with metastatic urothelial carcinoma.
For women with invasive lobular carcinoma, pathogenic variants in breast cancer risk genes predict high odds of early recurrence.
Higher background parenchymal enhancement on breast MRI may signal greater risk among women who carry BRCA mutations.
Patients with relapsed or refractory diffuse large B-cell lymphoma, who were ineligible for autologous stem cell transplant, were randomly assigned to receive Pola-R-GemOx or R-GemOx.
1.
Pomalidomide Reduces Severe Epistaxis in Hereditary Bleeding Disease.
2.
Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer
3.
healthy despite having advanced cancer.
4.
Breast awareness: What to look for in your self-exam
5.
Significant differences in breast cancer care still exist, but surgeons can change.
1.
The Genetics of Bernard Soulier Syndrome: What We Know so Far
2.
Modern Perspectives in Hematology for Modern Medicine
3.
Everything You Need to Know About the Latest Hyponatremia Algorithm
4.
HSC Failure in Fanconi Anemia: Mechanisms, Models, and Emerging Therapeutic Pathways
5.
Exploring the Mystery of Angiokeratomas on Scrotum: Causes, Symptoms and Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
2.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
4.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge